Cardiff Oncology, Inc. (CRDF)

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

Cardiff Oncology, Inc. (CRDF) is down 69.6% since the beginning of the year. At $1 per share, CRDF is trading 74.2% below its 52-week high of $3. Investors who bought $1,000 worth of CRDF shares 5 years ago would now be looking at an investment worth $161.

Cardiff Oncology, Inc. (CRDF) has returned -69.56% so far this year and -67.60% over the past 12 months. Over the last ten years, CRDF has returned -45.93% per year, falling short of the S&P 500 Index benchmark, which averaged 13.26% annually.

Based on dividend-adjusted daily data since Jul 27, 2004, CRDF's average daily return is +0.12%, while the average monthly return is +1.22%. At this rate, an investment would double in approximately 4.8 years.

Historically, 39% of months were positive and 61% were negative. The best month was Jul 2011 with a return of +356.3%, while the worst month was Jun 2018 at -73.3%. The longest winning streak lasted 5 consecutive months, and the longest losing streak was 10 months.

On a daily basis, CRDF closed higher 35% of trading days. The best single day was Jul 11, 2011 with a return of +172.2%, while the worst single day was Jun 8, 2018 at -48.0%.

Cardiff Oncology, Inc. has an annualized alpha of 25.45%, beta of 0.60, and R2 of 0.01 versus S&P 500 Index. Calculated based on daily prices since July 27, 2004.

• This stock participated in 140.04% of S&P 500 Index downside but only -31.35% of its upside - more exposed to losses than it benefited from rallies.
• Beta of 0.60 may look defensive, but with R2 of 0.01 this stock is largely uncorrelated with S&P 500 Index - low beta reflects independence, not downside protection. See the Volatility section for a true picture of this stock's risk.
• R2 of 0.01 means this stock moves largely independently of S&P 500 Index - capture ratios reflect limited market correlation rather than active downside protection. Consider using a more representative benchmark.

CRDF ranks 10 for risk / return — above 10% of stocks peers on PortfoliosLab. Its historical combined result is below most peers; review the five component ranks for context.

The Drawdowns chart displays portfolio losses from any high point along the way. Drawdowns are calculated considering price movements and all distributions paid, if any.

The table below displays the maximum drawdowns of the Cardiff Oncology, Inc.. A maximum drawdown is a measure of risk, indicating the largest reduction in portfolio value due to a series of losing trades.

The maximum drawdown for the Cardiff Oncology, Inc. was 99.96%, occurring on Mar 18, 2020. The portfolio has not yet recovered.

The current Cardiff Oncology, Inc. drawdown is 99.96%.

The chart below shows the rolling one-month volatility.

The chart below illustrates the trends in the financial health of Cardiff Oncology, Inc. over time, highlighting three key metrics: Total Revenue, Earnings Before Interest and Taxes (EBIT), and Net Income.

The Valuation section provides an overview of how Cardiff Oncology, Inc. is priced in the market compared to other companies in the Biotechnology industry. It includes key financial ratios that help investors assess whether the stock is undervalued or overvalued.